Caplin Point Laboratories is a pharmaceutical company with a unique business model, catering predominantly to emerging markets of Latin America and Africa said that its subsidiary Caplin Steriles (Caplin) has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 6 mg/0.5 mL (12 mg/mL) Single dose Vials, a generic therapeutic equivalent version of (RLD), IMITREX Injection, of GlaxoSmithKline, USA.

Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache. According to IQVIATM (IMS Health), Sumatriptan Injection had US sales data of approximately USD 5 million for the 12-month period ending March 2021, for Vial presentation.

Shares of the company gained Rs 0.75, or 0.11%, to settle  at  Rs 690.25.  The total volume of shares traded  was  15,754 at  the BSE (Wednesday).